Lundbeck announces plans to cut a fifth of R&D workforceLundbeck has announced plans to cut its research and development team, which could lead to a reduction of Share XLundbeck announces plans to cut a fifth of R&D workforcehttps://pharmaphorum.com/news/lundbeck-announces-plans-to-cut-around-160-rd-jobs/
After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival AjovySeveral months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed Share XAfter rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovyhttps://pharmaphorum.com/news/novartis-aimovig-for-migraine-nice-backs-teva-rival/
FDA approves ‘potential blockbuster’ migraine jab from LundbeckThe FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs Share XFDA approves ‘potential blockbuster’ migraine jab from Lundbeckhttps://pharmaphorum.com/news/fda-approves-potential-blockbuster-migraine-jab-from-lundbeck/
After rejection, NICE agrees to look again at migraine drug AimovigThe UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS Share XAfter rejection, NICE agrees to look again at migraine drug Aimovighttps://pharmaphorum.com/news/nice-migraine-aimovig/
FDA approves Allergan’s migraine tablet ahead of AbbVie mergerAllergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with Share XFDA approves Allergan’s migraine tablet ahead of AbbVie mergerhttps://pharmaphorum.com/news/fda-approves-allergans-migraine-tablet-ahead-of-abbvie-merger/
Allergan builds case for migraine drug ubrogepant as FDA verdict nearsAllergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved Share XAllergan builds case for migraine drug ubrogepant as FDA verdict nearshttps://pharmaphorum.com/news/allergan-builds-case-for-migraine-drug-ubrogepant-as-fda-verdict-nears/
FDA approves Lilly’s new migraine attack drug, rival from Allergan could followThe FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms Share XFDA approves Lilly’s new migraine attack drug, rival from Allergan could followhttps://pharmaphorum.com/news/fda-approves-lillys-new-migraine-attack-drug-rival-from-allergan-could-follow/
Blow to Novartis as NICE rejects migraine drug Aimovig againAfter NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with Share XBlow to Novartis as NICE rejects migraine drug Aimovig againhttps://pharmaphorum.com/news/blow-to-novartis-as-nice-rejects-migraine-drug-aimovig-again/
Lundbeck to acquire Alder, and migraine drug, for $1.95bnLundbeck is to acquire Alder BioPharmaceuticals and its late-stage migraine drug eptinezumab in a deal worth up to Share XLundbeck to acquire Alder, and migraine drug, for $1.95bnhttps://pharmaphorum.com/news/lundbeck-to-acquire-alder-and-migraine-drug-for-1-95bn/
